Clinical Features and Treatments of Syphilitic Uveitis: A Systematic Review and Meta-Analysis

Purpose. To investigate the clinical features and efficacies of treatments for syphilitic uveitis. Methods. PubMed was searched for studies of syphilitic uveitis published between January 1990 and October 2016. The clinical features were summarized and appraised. The pooled success rate was defined...

Full description

Bibliographic Details
Main Authors: Ting Zhang, Ying Zhu, Gezhi Xu
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2017/6594849
Description
Summary:Purpose. To investigate the clinical features and efficacies of treatments for syphilitic uveitis. Methods. PubMed was searched for studies of syphilitic uveitis published between January 1990 and October 2016. The clinical features were summarized and appraised. The pooled success rate was defined as an improved or maintained final visual acuity and was calculated with 95% confidence intervals (CIs). Heterogeneity, subgroup analysis, sensitivity analysis, and publication bias were assessed. Results. Thirty-two studies involving 670 patients were analyzed. The most common type of syphilitic uveitis was papillitis. The pooled success rate was 0.91 (95% CI 0.84–0.97) for antibacterial agents alone (15 studies, 286 patients); 0.95 (95% CI 0.91–0.98) for antibacterial agents and systemic corticosteroids combined (11 studies, 245 patients); and 0.91 (95% CI 0.80–0.98) for antibacterial agents, systemic corticosteroids, and other immunosuppressants combined (3 studies, 73 patients). Subgroup analyses revealed no correlations of the efficacy of antibacterial agent monotherapy with study characteristics, such as human immunodeficiency virus coinfection status. Conclusions. This systematic review and meta-analysis revealed the efficacy of antibacterial agents for treating syphilitic uveitis. Coadministration of systemic corticosteroids or immunosuppressants did not elicit further improvements in the clinical outcomes of antibacterial agents.
ISSN:2090-004X
2090-0058